Rangering i aksjer
#13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Handel Sensorion SA (ALSEN)
Pris ALSEN pris med markedsverdi på B
Markedsverdi av Sensorion SA(ALSEN)
Markedsverdi: $94.19M
Per July 2026 har Sensorion SA en markedsverdi på $94.19M. Dette gjør Sensorion SA til det 13314th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Sensorion SA fra 2015 til 2026
ALSEN sammenlignet med topp 5 mest populære stocks
| Pris på ALSEN |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.055T
|
+5,367,199.62%
|
|
|
|
|
$4.748T
|
+5,041,119.38%
|
|
|
|
|
$4.310T
|
+4,576,070.70%
|
|
|
|
|
$2.875T
|
+3,052,417.88%
|
|
|
|
|
$2.652T
|
+2,815,687.76%
|
